JOHNSON & JOHNSON is 295.8x more valuable than Avidity Biosciences, Inc. by market capitalization ($573.71 B vs $1.94 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RNA | JNJ |
|---|---|---|
| Market cap | $1.94 B | $573.71 B |
| US-listed rank | #2127 | #20 |
| Revenue (latest FY) | $18.75M | $94.19B |
| Net income (latest FY) | -$684.63M | $26.80B |
| Net margin | -3650.4% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 547 | 984 |
JOHNSON & JOHNSON is 295.8x more valuable than Avidity Biosciences, Inc. by market capitalization ($573.71 B vs $1.94 B).
In their latest fiscal years, Avidity Biosciences, Inc. reported $18.75M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Avidity Biosciences, Inc. and JOHNSON & JOHNSON, or browse the full rankings.